T lymphocytes as potential therapeutic drug carrier for cancer treatment

Steinfeld, Ute; Pauli, Christine; Kaltz, Nikolas; Bergemann, Christian; Lee, Hyeck-Hee

doi:10.1016/j.ijpharm.2005.12.040

Cited by 59 publications

(39 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…108 The cytotoxic antibiotic doxorubicin has also been delivered using Target MAG-doxorubicin NPs loaded onto T cells. 109 A selective drug carrier system involving antibody-coupled NPs is also an attractive drug-targeting system. Not only would they allow incorporation of cytotoxic antitumor drugs into the NP matrix, but they can also be routed by attachment of antibodies to a specific tumor cell type.…”

Section: T Cell Targetingmentioning

confidence: 99%

Potential applications of nanoparticles in cancer immunotherapy

Jia

Omri

Krishnan

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

In recent years considerable progress has been made in the field of cancer immunotherapy whereby treatments that modulate the body's own immune system are used to combat cancer. This has the potential to not only elicit strong anti-cancer immune responses which can break pre-existing tolerance and help promote tumor regression, but could also induce immunological memory which may help prevent tumor recurrence. In order to ensure effective delivery of immunotherapeutic agents, such as vaccines, checkpoint inhibitors, chemotherapeutic agents and nucleic acids, a safe and effective delivery system is often required. One such approach is the use of multifunctional nanoparticles (NPs), such as liposomes, polymers, micelles, dendrimers, inorganic NPs, and hybrid NPs, which have the potential to combine the delivery of a diverse range of therapeutic immunomodulators thereby increasing the efficacy of tumor cell killing. This review focuses on recent progress in NP-mediated immunotherapy for the treatment of cancer.

show abstract

Section: T Cell Targetingmentioning

confidence: 99%

Potential applications of nanoparticles in cancer immunotherapy

Jia

Omri

Krishnan

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…This suggests that by engineering the surface of the nanomaterials one may modulate their uptake into and/or release from the cell carriers to optimize the therapeutic regimen. The phosphatidylserinecontaining negatively charged liposomes were shown to increase therapeutic activity of an encapsulated anti-fungal agent, chloroquine, against C. neoformans infection in the mouse brain [36]. The chloroquine-loaded liposomes accumulated inside macrophage phagolysosomes and resulted in a remarkable reduction in fungal load in the brain even at low doses compared to the free drug at high doses, thus increasing the anti-fungal activity of macrophages.…”

Section: Cell-mediated Delivery Of Nanocarriers To Brainmentioning

confidence: 99%

Nanomedicine for Neurological Disorder

Kumar¹,

Kumar²

2014

Nanotechnology and Nanomaterials in the Treatment of Life-Threatening Diseases

View full text Add to dashboard Cite

“…A Phase II clinical study in patients with primary liver cancer was conducted using these MNPs, although the trial was not successful. Chemicell GmbH has commercialized TargetMAG-doxorubicin NPs (Steinfeld and Pauli 2006) involving a multidomain magnetite core and a cross-linked starch matrix with terminal cations that can be reversibly exchanged by the positively charged doxorubicin. The particles have a hydrodynamic diameter of 50 nm and are coated with 3 mg/ml doxorubicin.…”

Section: Drug Deliverymentioning

confidence: 99%